Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma

Patients with severe eosinophilic asthma (SEA) suffer from frequent asthma exacerbations, where eosinophils are major effector cells in airway inflammation, and anti-interleukin (IL)-5 becomes an effective treatment modality to control eosinophilic inflammation of SEA. Fifteen patients with SEA who...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Jae-Hyuk, Woo, Seong-Dae, Lee, Youngsoo, Kim, Chang-Keun, Shin, Yoo Seob, Ye, Young-Min, Park, Hae-Sim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840863/
https://www.ncbi.nlm.nih.gov/pubmed/33474865
http://dx.doi.org/10.4168/aair.2021.13.2.330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840863/
https://www.ncbi.nlm.nih.gov/pubmed/33474865
http://dx.doi.org/10.4168/aair.2021.13.2.330

Ejemplares similares